» S100MAP

PARTNERS and OBJECTIVES

OBJECTIVES RESULTS

Consortium partners:

Project coordinatorFundeni Clinical Institute

P1-Institute of Cellular Biology and Pathology N. Simionescu,

P2-Stefan S. Nicolau Institute of Virology (IVN)

P3-“Oncological Institute “Prof. Dr. Al. Trestioreanu”

P4-Rntech France

The main objective of this project was to examine the role of signaling pathways in pancreatic ductal adenocarcinomas (PDAC) progression, with the long-term goal of finding new approaches for improved therapies for this highly lethal disease. The project also aimed to set up a partnership in a priority research field – cancer genomics – to identify new molecular mechanisms involved in PDAC progression and designing new therapeutic approaches targeting these pathways. In doing so, we had consolidated the expertise and maintained the critical mass of scientists in areas of excellence. The unifying hypothesis of this proposal was that targeting tumor-stroma interaction in PDAC was a valid therapeutic approach. Moreover, we aimed to attract leading scientists from USA and Japan to directly participate in project development.

1. Dima S, Chivu-Economescu M, Purnichescu-Purtan R, Nastase A, Bacalbaşa N, Florea R, Bleotu C, Diaconu C, Duda DG, Herlea V, Popescu I. MAP4K4 Expression is Selectively Upregulated and Increases Cell Invasion in Pancreatic Ductal Adenocarcinoma. Transl. Med. Res,2016. 21(1):32-37.
2. Botezatu A*, Bleotu C, Nastase A, Anton G, Bacalbasa N, Duda D, Dima S*, Popescu I. Epigenetic Silencing of GNMT Gene in Pancreatic Adenocarcinoma.. (*) co – corresponding author.Cancer Genomics Proteomics,2015. 12: 21-30.
3. Cucu D, Chiritoiu G, Petrescu S, Babes A, Stanica L, Duda DG, Horii A, Dima S, Popescu I. Characterization of functional transient receptor potential melastatin 8 channels in human pancreatic ductal adenocarcinoma cells. Pancreas, 2014.43: 795-800.
4. Boteanu R, Suica V, Uyy E, Ivan L, Dima S, Popescu I, Simionescu M, Antohe F.Alarmins in chronic noncommunicable diseases: Atherosclerosis, diabetes and cancer. Journal of Proteomics, 153:21-29.(ISSN:1874-3919).